COSTAR predicts drug activity tested in glioblastoma samples
A learned drug-target connectivity signature selected 23 predicted hits and 25 negatives for testing in four glioblastoma patient samples. Ex-vivo measurements agreed with predictions at a reported mean ROC AUC of 0.94. The small validation establishes a bounded drug-activity prediction result, not clinical response. Vortioxetine was found by the initial experimental screen and is not attributed to COSTAR nomination.
Technology: COSTAR logistic LASSO drug-target model
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Newly selected compounds were tested ex vivo across four patient samples.
- Still unknown: Patient benefit, generalization and clinical safety remain unestablished.
- AI role: COSTAR logistic LASSO drug-target model supported the stated study; experimental and interpretive work remained with researchers.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11564103/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Primary full-text model Methods and selected experimental Results, publication metadata and affiliations; supplements not reviewed..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.